Convatec

Convatec launches new Esteem Body™ with Leak Defense™

Retrieved on: 
Monday, April 15, 2024
Consensus, International, Skin, Tension, FEA, Research, Finite element method, McNichol, Convatec, Patent, NCD, Leak, Stoma, Lancet, Nursing

BRIDGEWATER, N.J., April 15, 2024 /PRNewswire/ -- Convatec, a leading global medical products and technologies company, today announces that it has launched Esteem Body™ with Leak Defense™ in the United States. 

Key Points: 
  • BRIDGEWATER, N.J., April 15, 2024 /PRNewswire/ -- Convatec, a leading global medical products and technologies company, today announces that it has launched Esteem Body ™ with Leak Defense™ in the United States.
  • The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours.
  • Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'.
  • (January 11, 2024) Impact of Stoma Baseplate Convexity on Tension and Compression Around the Stoma Site: A Finite Element Analysis.

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Retrieved on: 
Tuesday, February 13, 2024
Wearables, Mobile Technology, Apps, Applications, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Health, Tandem, Convatec, Dexcom, CGM, IPhone, Multimedia, G6, Compatibility, Control, Insulin, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
  • View the full release here: https://www.businesswire.com/news/home/20240213214991/en/
    Tandem Mobi, the world’s smallest, durable insulin delivery system, now shipping in the United States.
  • The Tandem Customer Care team is available now to help determine eligibility and potential timing of pump shipments for customers.
  • People living with diabetes interested in the Tandem Mobi system can start the order process at: www.tandemdiabetes.com/mobi .

Why are manufacturing companies moving to the Dominican Republic?

Retrieved on: 
Wednesday, December 20, 2023
Fresenius (company), Cardinal Health, Dominican, MICM, Outsourcing, Electronics, Rockwell Automation, Commerce, Heart, Jabil, Stoma, Ministry, Traction, Investment, Convatec, Airline

SANTO DOMINGO, Dominican Republic, Dec. 20, 2023 (GLOBE NEWSWIRE) -- In a bold strategy that has revolutionized the international investment landscape, a growing number of free zone companies are making the Dominican Republic their top choice, relocating their businesses, as well as their production plants.

Key Points: 
  • SANTO DOMINGO, Dominican Republic, Dec. 20, 2023 (GLOBE NEWSWIRE) -- In a bold strategy that has revolutionized the international investment landscape, a growing number of free zone companies are making the Dominican Republic their top choice, relocating their businesses, as well as their production plants.
  • This robust tax exemption framework, under Law 8-90, grants complete exemptions, amounting to 100% for nearly all national and local taxes.
  • Companies enjoy no logistical complications thanks to the proximity to key markets in the United States and Europe.
  • The Dominican Republic's nearshoring success stories span across various industries, with several multinational companies choosing to move their operations to the country.

Key Players in the Global Wound Cleanser Market Showcase Innovative Solutions - Report Profiles Leading Companies and Their Contributions to Wound Care - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Diabetes, Chemicals, Plastics, Health, Manufacturing, Law Enforcement, Emergency Services, Other Health, Surgery, Medical Devices, Infectious Diseases, General Health, Hospitals, Other Manufacturing, Nursing, Medical Supplies, Argentum, Incidence, Partnership, NovaBay Pharmaceuticals, Medline Industries, Defense, Skin, FDA, LP, Göran Gentele, Growth, Inc., Defense Logistics Agency, Convatec, Smith & Nephew, Patient, Cosmetics, Limited

In November 2022, InfuSystem Holdings, Inc. and Sanara MedTech Inc. formed a partnership for SI Wound Care, LLC, offering innovative wound care solutions.

Key Points: 
  • In November 2022, InfuSystem Holdings, Inc. and Sanara MedTech Inc. formed a partnership for SI Wound Care, LLC, offering innovative wound care solutions.
  • What are the major market drivers, challenges, and opportunities in the global wound cleanser market?
  • What is the growth potential of the global wound cleanser market in North America, Europe, Asia-Pacific, and Latin America and Rest-of-the-World?
  • What is the supply chain scenario in the global wound cleanser market?

Convatec Group PLC: Scrip Dividend - Total Issued Shares

Retrieved on: 
Saturday, September 16, 2023
Official List, Convatec, Dividend, Date, London, London Stock Exchange, Financial Conduct Authority, Holding company

The Board of Directors of Convatec declared an interim dividend in respect of 2023 of 1.769 cents per share ("Interim Dividend").

Key Points: 
  • The Board of Directors of Convatec declared an interim dividend in respect of 2023 of 1.769 cents per share ("Interim Dividend").
  • On 2 August 2023, the Company announced that a scrip dividend would be made available for the Interim Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares.
  • Following the issue of shares under the scrip dividend scheme in respect of the Interim Dividend, the Company's issued share capital will be 2,049,789,559 ordinary shares of 10 pence each.
  • Dealings in the shares issued under the scrip dividend scheme are expected to commence on 28 September 2023.

Convatec Group PLC: Scrip Dividend – Calculation Price

Retrieved on: 
Friday, August 25, 2023
Convatec, Computershare, Interim, Dividend, Evergreen, Calculation, CREST, BST, Holding company

On 2 August 2023, the Board of Directors of Convatec Group Plc (“Convatec” or “the Company”) declared an interim dividend of 1.769 cents per share (“Interim Dividend”).

Key Points: 
  • On 2 August 2023, the Board of Directors of Convatec Group Plc (“Convatec” or “the Company”) declared an interim dividend of 1.769 cents per share (“Interim Dividend”).
  • A scrip dividend will be made available for this Interim Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares.
  • The “Calculation Price” for the issue of new ordinary shares under the scrip dividend scheme is:
    221.0 pence for each new ordinary share.
  • Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered.

Tandem Mobi, World’s Smallest Durable Insulin Delivery System, Receives FDA Clearance

Retrieved on: 
Tuesday, July 11, 2023
Professional Services, Business, Finance, AID, Insulin, Food and Drug Administration, Clothing, Tandem, Convatec, Miniaturization, Tandem Diabetes Care, Control, FDA, Family, Food, Medical device

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up, expanding the company’s portfolio of products.

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up, expanding the company’s portfolio of products.
  • The Tandem Mobi is fully controllable from a mobile app and is the world’s smallest durable automated insulin delivery system.1
    “Testing the limits of pump miniaturization, Tandem Mobi joins the t:slim X2 pump in our family of insulin delivery solutions bringing new options in wearability, the flexibility to disconnect, and full phone control,” said John Sheridan, president and chief executive officer.
  • AID Compatibility – Designed for use as part of an automated insulin delivery (AID) system, the Tandem Mobi features Control-IQ technology.
  • A limited release of Tandem Mobi is expected to start in late 2023 with full commercial availability planned in early 2024.

Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Wyeth, IPO, Doctor of Philosophy, MBA, BD (company), CareFusion, The Canadian Journal of Economics and Political Science, Accounting, Rutgers University, Advanz Pharma, Convatec, MD, Patient, Mylan, Allegheny College, Knowledge, LOS, Management, Economics, Pfizer

LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.  Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.

Key Points: 
  • Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of Mylan N.V.
    Mr. Borkowski is also the former Chief Financial Officer of CareFusion, which was ultimately acquired by Becton Dickinson for $12.2 billion
    LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.
  • Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.
  • After joining Mylan in 2002, Mr. Borkowski held positions of increasing responsibility including Chief Financial Officer and Executive Vice President from 2002 until 2009.
  • In addition to his experience at Mylan, Mr. Borkowski was the former Chief Financial Officer of CareFusion, where he led the IPO.

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Wyeth, IPO, Doctor of Philosophy, MBA, BD (company), CareFusion, The Canadian Journal of Economics and Political Science, Accounting, Rutgers University, Advanz Pharma, Convatec, MD, Patient, Mylan, Allegheny College, Knowledge, LOS, Management, Economics, Pfizer

LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.  Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.

Key Points: 
  • Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.
  • After joining Mylan in 2002, Mr. Borkowski held positions of increasing responsibility including Chief Financial Officer and Executive Vice President from 2002 until 2009.
  • In addition to his experience at Mylan, Mr. Borkowski was the former Chief Financial Officer of CareFusion, where he led the IPO.
  • Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Mr.

Generational Equity Advises Red Oak Medical Supply in Its Sale to Private Investor

Retrieved on: 
Thursday, June 15, 2023
Medical Supplies, Finance, Hospitals, Banking, Business, Professional Services, Small Business, Practice Management, Health, Institute for Private Investors, Central Region, ROMS, Senior, Jobst, Equity, Innogen, MEDLINE, Hollister, Sale, M&A, Nova, Pleasure, Convatec, Bariatrics, Nursing, Respironics, ResMed, Invacare

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Emaan Medical Supply, Inc. (dba, Red Oak Medical Supply) to a Private Investor.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Emaan Medical Supply, Inc. (dba, Red Oak Medical Supply) to a Private Investor.
  • Founded in 1997, Red Oak Medical Supply (ROMS), located in Houston, Texas, is one of the leading medical supply retailers in Houston.
  • With more than 10,000 unique items in stock, ROMS is truly a one-stop-shop for all medical supplies in Houston.
  • "It was a pleasure working with the seller and buyer as both have similar values,” said Farahmandi.